CareDx Q2 Adj EPS $(0.18) Beats $(0.31) Estimate, Sales $70.30M Beat $61.76M Estimate
Portfolio Pulse from vinayak@benzinga.com
CareDx reported Q2 adjusted EPS of $(0.18), beating the estimate of $(0.31) by 41.94%. The company's quarterly sales were $70.30M, surpassing the estimate of $61.76M by 13.83%. However, these figures represent a decrease from the same period last year.
August 08, 2023 | 8:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CareDx's Q2 results exceeded estimates but are lower than last year's figures.
While CareDx beat estimates for Q2, the decrease from last year's figures may cause some concern among investors. This could potentially lead to a neutral short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100